Novo Nordisk

Thumbnail for Novo Nordisk announces positive Phase 3 results for CagriSema

13 March 2025

Novo Nordisk announces positive Phase 3 results for CagriSema

Thumbnail for Novo Nordisk plans new Phase III trial to strengthen CagriSema’s efficacy data

11 February 2025

Novo Nordisk plans new Phase III trial to strengthen CagriSema’s efficacy data

Thumbnail for Novo Nordisk’s Amycretin shows promising weight loss in early trials

2 February 2025

Novo Nordisk’s Amycretin shows promising weight loss in early trials

Thumbnail for Novo Nordisk reports promising results from STEP UP Trial on obesity treatment

20 January 2025

Novo Nordisk reports promising results from STEP UP Trial on obesity treatment

Thumbnail for Novo Nordisk and Valo Health expand collaboration on AI-driven drug development

9 January 2025

Novo Nordisk and Valo Health expand collaboration on AI-driven drug development

Thumbnail for Novo Nordisk invests US$1.2 B in new production facility in Odense, Denmark

16 December 2024

Novo Nordisk invests US$1.2 B in new production facility in Odense, Denmark

Thumbnail for Ypsomed to supply pens for Novo Nordisk’s CagriSema

22 November 2024

Ypsomed to supply pens for Novo Nordisk’s CagriSema

Thumbnail for NanoVation secures funding, expands board

21 November 2024

NanoVation secures funding, expands board

Thumbnail for Novo Nordisk’s Semaglutide shows promise in treating liver disease

20 November 2024

Novo Nordisk’s Semaglutide shows promise in treating liver disease

Thumbnail for Sahpra warns of counterfeit diabetes drugs in South Africa

13 November 2024

Sahpra warns of counterfeit diabetes drugs in South Africa